Lv4
460 积分 2025-08-15 加入
Tislelizumab: First Approval
7个月前
已完结
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
7个月前
已完结
Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double‐blind, parallel‐controlled trial
8个月前
已完结
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
8个月前
已完结
Intracerebral Hemorrhage following Possible Interaction between Celecoxib and Clopidogrel
8个月前
已完结
NSAID Use in Individuals at Risk of Renal Adverse Events
8个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study
9个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
9个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
9个月前
已完结
Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
9个月前
已完结
皖公网安备34019202002308
